Combining Drugs May Improve Ovarian Cancer Survival
This study has already led to human trials
The exciting findings of this mouse experiment are already gaining attention in the scientific community. The team has recently published their findings in the December issue of Proceedings of the National Academy of Sciences. The data from this study has led to ongoing clinical trials, and patients with ovarian cancer are already being treated with a combination of 5-azacytidine and a checkpoint inhibitor. Depending on the efficacy seen in these preliminary trials, future trials may include the addition of histone deacetylase inhibitors to determine outcomes.
Reference
https://www.sciencedaily.com/releases/2017/12/171205104132.htm
